Nivolumab and pembrolizumab, PD-1 inhibitors, increase overall survival in recurrent or metastatic (R/M) HNSCC cases that worsen with platinum-related therapy. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.